Melbourne, 30 November 2024
Bellberry and ASCEPT (Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists) are pleased to release the summary report from the first NAMs workshop.
The introductory workshop brought together regulators, ethicists, researchers and industry leaders to consider how Australia can support the responsible use of NAMs, reduce reliance on animal models, improve translational outcomes and support the transition to first-in-human and early clinical trials.
The report summarises key themes from the workshop, including drivers for NAM adoption, validation, regulatory and ethical considerations, therapeutic scenarios explored by participants, and priorities for policy, funding and collaboration.
To download your copy of the summary report please enter your details below:
Please read the Bellberry Privacy Policy before submitting.